JP2002539805A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002539805A5 JP2002539805A5 JP2000607471A JP2000607471A JP2002539805A5 JP 2002539805 A5 JP2002539805 A5 JP 2002539805A5 JP 2000607471 A JP2000607471 A JP 2000607471A JP 2000607471 A JP2000607471 A JP 2000607471A JP 2002539805 A5 JP2002539805 A5 JP 2002539805A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- dendritic
- tumor
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 description 56
- 238000000034 method Methods 0.000 description 32
- 210000004443 dendritic cell Anatomy 0.000 description 22
- 210000001744 T-lymphocyte Anatomy 0.000 description 19
- 210000004881 tumor cell Anatomy 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 241000701806 Human papillomavirus Species 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 241000700584 Simplexvirus Species 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 210000003426 epidermal langerhans cell Anatomy 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- 230000000735 allogeneic effect Effects 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 210000000173 T-lymphoid precursor cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28267999A | 1999-03-31 | 1999-03-31 | |
| US09/282,679 | 1999-03-31 | ||
| PCT/US2000/008472 WO2000057705A1 (en) | 1999-03-31 | 2000-03-30 | In vitro induction of antigen-specific t-cells using dendritic cell-tumor cell or dendritic cell-viral cell derived immunogens |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002539805A JP2002539805A (ja) | 2002-11-26 |
| JP2002539805A5 true JP2002539805A5 (enExample) | 2007-06-07 |
Family
ID=23082644
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000607471A Pending JP2002539805A (ja) | 1999-03-31 | 2000-03-30 | 樹状細胞・腫瘍細胞または樹状細胞・ウイルス細胞由来免疫原を用いた抗原特異的ｔ細胞のインビトロ産生 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1168924A4 (enExample) |
| JP (1) | JP2002539805A (enExample) |
| CN (1) | CN1353575A (enExample) |
| AU (1) | AU4183100A (enExample) |
| CA (1) | CA2367590A1 (enExample) |
| WO (1) | WO2000057705A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050169898A1 (en) | 1997-04-15 | 2005-08-04 | Jianlin Gong | Cell fusions and methods of making and using the same |
| CA2286873C (en) | 1997-04-15 | 2010-07-13 | Dana-Farber Cancer Institute, Inc. | Dendritic cell hybrids |
| WO2001029193A2 (de) * | 1999-10-22 | 2001-04-26 | Peter Leskovar | Zellkonstrukte, die für die immuntherapie geeignet sind, deren herstellung und verwendung |
| EP1263928B1 (en) * | 2000-02-11 | 2007-09-26 | Dana-Farber Cancer Institute, Inc. | Identification of antigenic peptides by cytotoxic t lymphocytes activated by dendritic cell hybrids |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US7541184B2 (en) | 2000-02-24 | 2009-06-02 | Invitrogen Corporation | Activation and expansion of cells |
| DE10164819A1 (de) * | 2001-11-20 | 2005-05-19 | Deml, Ludwig, Dr. | Verfahren zur Identifizierung von Zielepitopen der T-Zell-vermittelten Immunantwort und zum Nachweis Epitop-spezifischer T-Zellen |
| ES2613957T3 (es) | 2006-08-04 | 2017-05-29 | Medimmune Limited | Anticuerpos contra ERBB2 |
| DE102010037622B4 (de) * | 2010-09-17 | 2012-07-12 | Lophius Biosciences Gmbh | Verfahren zum Nachweis, Differenzieren und Quantifizieren von T-Zellpopulationen mittels der Reverse Transkription quantitativen Real-Time PCR (RT-qPCR) Technologie |
| EP2606897A1 (en) | 2011-12-22 | 2013-06-26 | Laboratorios Del. Dr. Esteve, S.A. | Methods and compositions for the treatment of diseases caused by enveloped viruses |
| CN102827826B (zh) * | 2012-09-11 | 2017-07-04 | 赵永祥 | 一种诱导树突状细胞与肿瘤细胞融合的方法 |
| WO2016145578A1 (en) * | 2015-03-13 | 2016-09-22 | Syz Cell Therapy Co. | Methods of cancer treatment using activated t cells |
| CN104830793A (zh) * | 2015-05-05 | 2015-08-12 | 杨光华 | 基于lmp-1抗原的dc细胞、靶向性免疫细胞群及其制备方法和用途 |
| CA2985350A1 (en) | 2015-05-08 | 2016-11-17 | Wilson Wolf Manufacturing | Improved culture methods and devices for testing |
| JP2018522880A (ja) | 2015-07-02 | 2018-08-16 | プライムヴァックス イミュノ−オンコロジー，インク． | デングウイルス及び樹状細胞による併用療法のための組成物及び方法 |
| CA2999881A1 (en) | 2015-09-26 | 2017-03-30 | PrimeVax Immuno-Oncology, Inc. | Compositions and methods for producing dendritic cells |
| CN105532575A (zh) * | 2016-01-14 | 2016-05-04 | 中国科学院昆明动物研究所 | 一种单纯疱疹病毒感染树鼩动物模型的构建、评估方法及其应用 |
| CN110139671A (zh) | 2016-11-16 | 2019-08-16 | 普莱瓦克斯免疫肿瘤学公司 | 用于治疗癌症的组合免疫疗法 |
| WO2018129202A1 (en) | 2017-01-04 | 2018-07-12 | PrimeVax Immuno-Oncology, Inc. | Compositions and methods for therapy with dengue virus |
| WO2019183924A1 (en) | 2018-03-30 | 2019-10-03 | Syz Cell Therapy Co. | Improved multiple antigen specific cell therapy methods |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69634750T2 (de) * | 1995-03-31 | 2006-02-23 | Université Libre de Bruxelles | DENDRITENZELLEN/TUMORZELLEN Hybirde ZUR INDUKTION EINER ANTI-TUMOR ANTWORT |
| CA2286873C (en) * | 1997-04-15 | 2010-07-13 | Dana-Farber Cancer Institute, Inc. | Dendritic cell hybrids |
| CA2318987A1 (en) * | 1998-01-26 | 1999-07-29 | Genzyme Corporation | Immune effector cell hybrids |
-
2000
- 2000-03-30 AU AU41831/00A patent/AU4183100A/en not_active Abandoned
- 2000-03-30 WO PCT/US2000/008472 patent/WO2000057705A1/en not_active Ceased
- 2000-03-30 CA CA002367590A patent/CA2367590A1/en not_active Abandoned
- 2000-03-30 EP EP00921528A patent/EP1168924A4/en not_active Withdrawn
- 2000-03-30 CN CN00808298A patent/CN1353575A/zh active Pending
- 2000-03-30 JP JP2000607471A patent/JP2002539805A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002539805A5 (enExample) | ||
| Heemskerk et al. | Enrichment of an antigen-specific T cell response by retrovirally transduced human dendritic cells | |
| JP2006508664A (ja) | 抗原負荷した樹状細胞ワクチンを前駆体から発生させる迅速ワンステップ法 | |
| US7195758B2 (en) | Methods of inducing a T cell mediated immune response by administering antigen presenting B cells | |
| JP2002539805A (ja) | 樹状細胞・腫瘍細胞または樹状細胞・ウイルス細胞由来免疫原を用いた抗原特異的ｔ細胞のインビトロ産生 | |
| WO2009040413A2 (en) | An ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases | |
| Abdel-Wahab et al. | Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide (280-288), induce pairs of T-cell cultures with similar phenotype and lytic activity | |
| US20180078627A1 (en) | Method for antigen loading of dendritic cells and vaccine | |
| Wang et al. | An effective cancer vaccine modality: lentiviral modification of dendritic cells expressing multiple cancer-specific antigens | |
| JP6602377B2 (ja) | 樹状細胞の製造方法、これにより製造された樹状細胞及びその用途 | |
| WO2012137538A1 (ja) | 細胞傷害性ｔ細胞誘導用組成物 | |
| Mason et al. | RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma | |
| US20030082163A1 (en) | Fused cells, methods of forming same, and therapies utilizing same | |
| CN115698270A (zh) | 一种通过iPS细胞生产再生T细胞的方法 | |
| Nair et al. | RNA-transfected dendritic cells | |
| JP2002500872A5 (enExample) | ||
| EP3555266B1 (en) | Methods of preparing an isolated or purified population of thymic emigrant cells and methods of treatment using same | |
| EP1178822B1 (en) | Whole cell cancer vaccine comprising co-cultured malignant and non-malignant cells | |
| US20050170503A1 (en) | In vitro induction of antigen-specific T-cells using dendritic cell-tumor cell or dendritic cell-viral cell derived immunogens | |
| NZ508936A (en) | Method for preparation and in vivo administration of antigen presenting cell composition | |
| US20100291683A1 (en) | Modified Antigen Presenting Cells and Methods of Use | |
| CN118221773B (zh) | 与HLA相关的CMV pp65表位疫苗组合物与应用 | |
| WO1998021314A2 (en) | Method of promoting b-cell proliferation and activation and of modulating the immune system | |
| CN111166876A (zh) | 一种免疫增强剂组合和编码核酸及其应用 | |
| WO2020164167A1 (zh) | 一种用于通用型car-t制备的重组腺相关病毒载体及其构建方法和应用 |